Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05048732 · ClinicalTrials.gov registry record · Early Phase 1
Imaging Apoptosis for Lymphoma Treatment Response
A Early Phase 1 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 12
- Enrollment target
NCT05048732 is a Early Phase 1 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 12 participants.
The verdict
NCT05048732, a Early Phase 1 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
Apoptosis is a specific form of cell death that leads to clearance of dead cells without causing inflammation or injury to normal adjacent tissues. Targeted cancer therapeutics that target this pathway for tumor cell death induction are in development, but few specific biomarkers of apoptosis are available to assess treatment response. Apoptosis also occurs in response to standard anthracycline or combination therapies such as rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP), rituximab, etoposide, phosphate, prednisone, vincristine sulfacte, cyclophosphamide, and doxorubicin hydrocholoride (R-EPOCH) used to treat many different histopathological types of lymphoma including Hodgkin and non- Hodgkin lymphoma such as diffuse large B-cell lymphoma (DLBCL), Burkitts lymphoma, primary mediastinal B-cell lymphoma and double hit DLBCL. Caspase-3 activation occurs as a result of apoptosis and may be a specific marker of apoptosis. Therefore, this study will assess whether 18F-FluorApoTrace (18F-FAT), a caspase-3 targeted tracer, has a reasonable dosimetry profile and can be used to detect apoptosis in patients with lymphoma being treated with standard therapy.
Interventions
- DRUG 18F-FluorApoTrace
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-12-06 |
| Est. Completion | 2024-02-10 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05048732
The ClinicalTrials.gov registry entry for NCT05048732 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 18F-FluorApoTrace is the first listed.
NCT05048732 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05048732 about?
NCT05048732 is a clinical study titled "Imaging Apoptosis for Lymphoma Treatment Response". Apoptosis is a specific form of cell death that leads to clearance of dead cells without causing inflammation or injury to normal adjacent tissues. Targeted cancer therapeutics that target this pathway for tumor cell death induction are in development, but few specific biomarkers of apoptosis are av...
What is the current status of trial NCT05048732?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 12 participants. The study started on 2021-12-06. Estimated completion is 2024-02-10.
What interventions are being tested in trial NCT05048732?
The interventions under investigation include: 18F-FluorApoTrace (DRUG).
Who is sponsoring clinical trial NCT05048732?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.